台灣臨床試驗主持人資料庫|TPIDB

2018-06-01 - 2020-12-31

Phase III

Condition/Disease
Test Drug

Participate Sites
1Sites

Terminated1Sites

常敏之

Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2018-06-01 - 2022-11-15

Phase I

A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced Malignancies

Condition/Disease

Advanced Malignancies
Test Drug

Isatuximab

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting5Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

余明隆

Kaohsiung Municipal Gangshan Hospital

未分科

2016-03-15 - 2018-03-15

Phase III

A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex® With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis

Condition/Disease

Renal Anemia
Test Drug

UB-851

Participate Sites
18Sites

Recruiting10Sites

Terminated8Sites

唐德成

Taipei Veterans General Hospital

Division of Nephrology

2015-07-01 - 2020-12-31

Phase II

Multicenter, open-label, single arm, Phase II study in advanced non-small cell lung cancer；Subtitle:A multicenter, open-label, single arm Phase II study to evaluate safety and efficacy of ONO-4538 in stage IIIB/IV or recurrent non-small cell lung cancer patients who are unsuited to radical radiotherapy and resistant to a platinum-base chemotherapeutic regimen.

Condition/Disease

stage IIIB/IV or recurrent non-small cell lung cancer
Test Drug

Opdivo®

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated8Sites

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-02-01 - 2019-04-30

Phase III

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Condition/Disease

High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD)
Test Drug

RVX000222

Participate Sites
14Sites

Terminated14Sites

江晨恩

Taipei Veterans General Hospital

謝宜璋

Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2017-01-01 - 2020-06-30

Phase III

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction

Condition/Disease

Chronic Heart Failure
Test Drug

Forxiga

Participate Sites
15Sites

Terminated13Sites

江晨恩

Taipei Veterans General Hospital

Division of Cardiovascular Diseases

謝宜璋

Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2017-08-24 - 2019-09-30

Phase III

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

Condition/Disease

Small-Cell Lung Cancer (SCLC)
Test Drug

Durvalumab; Tremelimumab

Participate Sites
11Sites

Terminated10Sites

邱昭華

Taipei Veterans General Hospital

Division of Hematology & Oncology

夏德椿

China Medical University Hospital-Taipei

未分科

2018-11-19 - 2022-12-01

Phase III

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Condition/Disease

Heart Failure With Preserved Ejection Fraction (HFpEF)
Test Drug

dapagliflozin film-coated tablets

Participate Sites
15Sites

Recruiting13Sites

江晨恩

Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2016-04-01 - 2019-12-31

Phase III

Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled, Pivotal Phase III Clinical Study to Assess the Efficacy and Safety of Rexis® as an Add-on Therapy in Patients with Severe Sepsis and Septic Shock

Condition/Disease

Severe Sepsis and Septic Shock
Test Drug

Rexis®

Participate Sites
7Sites

Recruiting7Sites

陽光耀

Taipei Veterans General Hospital

Division of Thoracic Medicine

2016-03-14 - 2017-09-07

Phase III

A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Subjects with Chronic Hepatitis C Virus Genotype 1 – 6 Infection (MAGELLAN-2)

Condition/Disease

Post-Liver or Post-Renal Transplant Subjects with Chronic Hepatitis C Virus Genotype 1 – 6 Infection
Test Drug

ABT-493/ABT-530

Participate Sites
2Sites

Terminated2Sites

朱啟仁

Taipei Veterans General Hospital

Digestive System Department

Search Result

List